ArticlePostepy dermatologii i alergologii2024
Significance of HLA-B*15 in three pemphigus patients with rituximab-triggered severe cutaneous drug reactions.
Article in Postepy dermatologii i alergologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rituximab in Pemphigus - Exploring the Less Frequently Travelled Terrains.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rituximab, a CD20 inhibitor, has swiftly become the primary treatment for pemphigus patients. Aim: We present 3 cases of pemphigus patients who had undergone rituximab treatment. Material and methods: After the second intravenous administration of rituximab, the primary rash developed into severe cutaneous drug reactions. Peripheral blood was collected from the aforementioned 3 patients for the detection of susceptibility genes by using second-generation sequencing. Results: Notably, a significant resemblance was observed in the HLA profiles of these 3 patients, particularly regarding high-risk alleles associated with rituximab-induced severe cutaneous drug reactions (CDRs). This rare occurrence of severe CDRs post-rituximab administration may be HLA-dependent and linked to HLA-B*15:02:01, HLA-B*15:12 and HLA-B*15:27:01. This pioneering laboratory trial shows the pathological background of rituximab-induced severe cutaneous drug reactions. Conclusions: Our findings contribute to the expanding catalogue of potential HLA-B*15 linked to severe CDRs and underscore the importance of vigilance regarding such reactions in pemphigus patients undergoing rituximab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.